Skip to main content

Table 4 Change in immunostaining of carcinoma cells between pre-treatment and post-treatment, assessed by semi-quantitative analysis (n = 92)

From: Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial

  Groupa P-value
I (n = 33) II (n = 30) III (n = 29)
Bax immunostaining, n (%)     
 Decrease 0 (0.0) 0 (0.0) 1 (3.4) <0.001b
 No change 5 (15.2) 3 (10.0) 27 (93.1)
 Increase 28 (84.8) 27 (90.0) 1 (3.4)
Bcl-2 immunostaining, n (%)     
 Decrease 30 (90.9) 24 (80.0) 8 (27.6) <0.001b
 No change 3 (9.1) 4 (13.3) 18 (62.1)
 Increase 0 (0.0) 2 (6.7) 3 (10.3)
  1. aGroup I: chemotherapy and rAD-p53; group II: rAD-p53; group III: chemotherapy.
  2. b P-values are based on Fisher’s exact test.